Life Sciences
Life Sciences
Life Sciences
- $650
- MillionCapital Raised
- 80+
- YearsOf life sciences experience on the investing team
- 16
- Investments made to date
Source: Goldman Sachs Asset Management. Capital Raised as of December 31, 2024. Years of Experience and Investments made to date as of November 20, 2025.
We operate a robust, multi-channel sourcing engine that leverages Goldman Sachs’ relationships across academic and medical institutions, corporates, venture capital and private equity firms, and company founders and executives.
We believe that many life sciences companies would benefit from scaling privately, but a funding gap has historically forced these companies to go public too early. By better aligning investment capital with company innovation, we hope to drive better outcomes for companies and, ultimately, patients.
We strive to invest in innovative life sciences companies developing novel medicines that are entering or in the earlier stages of clinical development. By investing at a later-stage than traditional life sciences venture funds, WSLS I seeks to mitigate scientific risk while retaining the significant value creation associated with clinical translation. We believe the strategy has the potential to deliver strong returns over a shorter time period to our investors.
We partner with companies to enhance and accelerate value creation by helping them establish the right business and financial strategies, hire the right management team and board, execute, and achieve strong exits.
Source: Goldman Sachs Asset Management as of November 20, 2025. Investments were selected to highlight the largest investments made as of November 20, 2025. We believe these selected case studies should be considered as a reflection of our investment process, and references to these particular assets/portfolio companies should not be considered a recommendation of any particular security, investment, or portfolio company. Any mention of an investment decision is intended only to illustrate our investment strategy and is not indicative of the performance of our strategy as a whole. It should not be assumed that any investment decisions shown will prove to be profitable or any future investment decisions will be profitable or equal the performance of the investments discussed herein. The holdings and/or allocations shown may not represent all of the strategy’s investments. Please contact your Goldman Sachs Asset Management representative to obtain the holdings presented above as well as each holding’s contribution to performance and a complete list of past recommendations. Please see additional disclosures in the appendix.
- Precision Medicine
- Genetic Medicine
- Immunotherapy
- Scalable Platforms
- Market Dislocations
- Global Innovation
Precision Medicine
Precision medicine is the ability to deliver medicines that target a patient’s underlying cause of disease based on their genetics or other unique biological characteristics
Genetic Medicine
Genetic medicine is the ability to alter a patient’s gene expression to treat disease through the introduction or alteration of genetic material.
Immunotherapy
Immunotherapy is the ability to engage and manipulate the immune system as an approach to treating disease.
Scalable Platforms
Scalable platforms utilize common underlying technologies to prosecute a wide range of potential targets and diseases.
Market Dislocations
Market dislocations create an ability to invest in promising assets at attractive prices due to market volatility or changes in strategic direction.
Global Innovation
Global innovation represents the potential for substantial value creation by emerging companies outside the U.S. in regions such as Europe and China.
Source: Goldman Sachs Asset Management. As of December 31, 2024. This information discusses general market activity, industry or sector trends, or other broad-based economic, market or political conditions and should not be construed as research or investment advice. This material has been prepared by Goldman Sachs and is not financial research nor a product of Goldman Sachs Global Investment Research (GIR). It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed may differ from those of Goldman Sachs Global Investment Research or other departments or divisions of Goldman Sachs and its affiliates. Investors are urged to consult with their financial advisors before buying or selling any securities. This information may not be current and Goldman Sachs has no obligation to provide any updates or changes.
